KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Interest Expenses (2018 - 2025)

Historic Interest Expenses for Neogenomics (NEO) over the last 13 years, with Q3 2025 value amounting to $603000.0.

  • Neogenomics' Interest Expenses fell 6327.65% to $603000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 2840.88%. This contributed to the annual value of $6.6 million for FY2024, which is 419.86% down from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Interest Expenses is $603000.0, which was down 6327.65% from $933000.0 recorded in Q2 2025.
  • Neogenomics' 5-year Interest Expenses high stood at $5.2 million for Q4 2022, and its period low was $139000.0 during Q3 2022.
  • Moreover, its 5-year median value for Interest Expenses was $1.6 million (2024), whereas its average is $1.7 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first tumbled by 8927.47% in 2022, then skyrocketed by 111223.02% in 2023.
  • Quarter analysis of 5 years shows Neogenomics' Interest Expenses stood at $4.8 million in 2021, then grew by 7.64% to $5.2 million in 2022, then tumbled by 67.77% to $1.7 million in 2023, then dropped by 3.39% to $1.6 million in 2024, then crashed by 62.87% to $603000.0 in 2025.
  • Its Interest Expenses was $603000.0 in Q3 2025, compared to $933000.0 in Q2 2025 and $1.6 million in Q1 2025.